GF Fund Management’s Ligand Pharmaceuticals LGND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$155K Buy
495
+70
+16% +$20.7K ﹤0.01% 296
2026
Q2
$134K Sell
425
-18
-4% -$4.24K ﹤0.01% 304
2026
Q1
$88.4K Buy
443
+57
+15% +$11.3K ﹤0.01% 349
2025
Q4
$73K Sell
386
-36
-9% -$6.92K ﹤0.01% 372
2025
Q3
$74.8K Sell
422
-62
-13% -$9.22K ﹤0.01% 358
2025
Q2
$55K Hold
484
– – ﹤0.01% 406
2025
Q1
$50.9K Buy
484
+87
+22% +$9.8K ﹤0.01% 418
2024
Q4
$42.5K Hold
397
– – ﹤0.01% 403

Other funds holding LGND

GF Fund Management's LGND Position: Q3 2026 in Review

GF Fund Management increased its Ligand Pharmaceuticals (LGND) stake by 16% in Q3 2026, buying an estimated $20.7K and bringing the position to 495 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #296.

GF Fund Management first reported a position in LGND in Q4 2024 and has held it in 8 quarters since. 433 funds tracked by Wall St. Rank hold LGND as of Q3 2026.

  • GF Fund Management held 495 shares of Ligand Pharmaceuticals worth $155K as of Q3 2026.
  • GF Fund Management bought 70 Ligand Pharmaceuticals shares in Q3 2026, an estimated $20.7K.
  • Ligand Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #296 holding.
  • GF Fund Management first reported a position in Ligand Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • 433 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.